Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
May 8, 2026European Stroke JournalOpen Access

Abstract Number: Esoc2026ys26 Therapeutic Efficacy and Safety of Escitalopram for Post-Stroke Depression: Evidence From a Systematic Review and Meta-Analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

ISIbrahim SeragMMMostafa MoawadMAMohamed Abouzid

Discussion

Loading...

Member takes

Overview

Randomized trial evaluates escitalopram's efficacy in reducing post-stroke depression symptoms, suggesting its potential benefit.

Key Points

  • This research aims to determine the efficacy and safety of escitalopram in treating post-stroke depression compared to placebo.
  • Systematic review and meta-analysis following PRISMA guidelines
  • Included six randomized controlled trials with 1,197 participants
  • Data extracted included HAMD scores, NIHSS, Barthel Index, MoCA, and emotional incontinence outcomes.
  • Escitalopram improved HAMD scores by a mean difference of –3.01 (95% CI: –4.82 to –1.19; p = 0.001) among 229 patients.
  • Significant improvement in NIHSS with a mean difference of –1.74 (95% CI: –2.82 to –0.12; p = 0.03) in 777 patients.
  • Barthel Index scores improved by 13.17 points (95% CI: 11.34 to 15.00; p < 0.0001) among 574 patients.

Cite This Study

Serag et al. (2026) studied this question.

synapsesocial.com/papers/69fd7ec6bfa21ec5bbf07113https://doi.org/10.1093/esj/aakag023.1147
View Full Paper
Ask AI
Bookmark
Share